WH-4-023 (Synonyms: Dual LCK/SRC inhibitor) |
| رقم الكتالوجGC13600 |
WH-4-023 هو مثبط Lck / Src مزدوج قوي وانتقائي مع IC 50 من 2 نانومتر / 6 نانومتر لـ Lck و Src كيناز على التوالي ؛ القليل من التثبيط على p38α و KDR
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 837422-57-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
WH-4-023 is a potent and selective Lck and Src inhibitor with IC50 values of 2 and 6 nM, respectively [1]. It is also an inhibitor of IC50 values of 10, 22 and 60 nM for SIK 1, 2 and 3, respectively [2].
Lck and Src are cytoplasmic tyrosine kinases of the Src family expressed in T cells and NK cells [1]. SIKs restrict the formation of regulatory macrophages and that their inhibition greatly stimulates the production of IL-10 and other anti-inflammatory molecules [2].
WH-4-023 inhibited a number of protein tyrosine kinases that possess a Thr residue at the gatekeeper site, such as FGF and Ephrin receptors, Src family members (Src, Lck, and Yes) and BTK. WH-4-023 also inhibited the SIKs and did not inhibit any other member of the AMPK-related kinase subfamily, which all possess a large hydrophobic residue (Met or Leu) at the gatekeeper site. WH-4-023 inhibited SIK 1, 2 and 3 with IC50 values of 10, 22 and 60 nM, respectively. Also, WH-4-023 increased LPS-stimulated IL-10 production and greatly suppressed proinflammatory cytokine secretion [2].
References:
[1]. Martin MW, Newcomb J, Nunes JJ, et al. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem, 2006, 49(16): 4981-4991.
[2]. Clark K, MacKenzie KF, Petkevicius K, et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A, 2012, 109(42): 16986-16991.
| Kinase experiment[1]: | |
|
Lck kinase assays |
To determine the inhibitory activity of WH-4-023 against Lck, kinase assays were conducted. The Lck HTRF kinase assay involved ATP-dependent phosphorylation of a biotinylated substrate peptide of gastrin with or without WH-4-023. The final concentration of ATP, gastrin and Lck were 0.5 μM, 1.2 μM and 250 pM, respectively. Buffer were made up as follows: 50 mM HEPES pH=7.5, 2 mM DTT, 5 mM MnCl2, 20 mM MgCl2, 50 mM NaCl, 0.05% BSA. The reaction was quenched and ended by adding 160 μL detection reagent. Detection reagent was prepared as follows: 50 mM Tris, pH=7.5, 3 mM EDTA, 100 mM NaCl, 0.05% BSA, 0.1% Tween-20. Before reading, streptavidin allophycocyanin and anti-phosphotyrosine Ab were added at a final concentration of 0.4 μg/mL and 0.025 nM, respectively. Assay plate was read with excitation at 320 nm and emission at 615 and 655 nm. |
| Cell experiment[2]: | |
|
Cell lines |
Naive human pluripotent cells |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
1 μM |
|
Applications |
WH-4-023 is a potent and selective Src and Lck inhibitor with IC50 values of 6 and 2 nM, respectively[1].Naive human pluripotent cells were maintained in media containing WH-4-023. WH-4-023 improves the fraction of viable GFP+ cells. Withdrawal of the WH-4-023 results in a change in morphology and slight decrease of OCT4-DPE-GFP reporter activity[2]. |
|
References: [1]. Martin M W, Newcomb J, Nunes J J, et al. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity[J]. Journal of medicinal chemistry, 2006, 49(16): 4981. [2]. Theunissen T W, Powell B E, Wang H, et al. Systematic Identification of Defined Conditions for Induction and Maintenance of Naive Human Pluripotency[J]. Cell stem cell, 2014, 15(4): 471. | |
| Cas No. | 837422-57-8 | SDF | |
| المرادفات | Dual LCK/SRC inhibitor | ||
| Chemical Name | 2,6-dimethylphenyl (2,4-dimethoxyphenyl)(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)carbamate | ||
| Canonical SMILES | CN1CCN(C2=CC=C(NC3=NC(N(C4=CC=C(OC)C=C4OC)C(OC5=C(C)C=CC=C5C)=O)=CC=N3)C=C2)CC1 | ||
| Formula | C32H36N6O4 | M.Wt | 568.67 |
| الذوبان | ≥ 56.9mg/mL in DMSO | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7585 mL | 8.7924 mL | 17.5849 mL |
| 5 mM | 0.3517 mL | 1.7585 mL | 3.517 mL |
| 10 mM | 0.1758 mL | 0.8792 mL | 1.7585 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *